Argos Therapeutics, Inc. shares had a trading volume of 855K by the end of trading on Tuesday. Overall, volume was down 78.86% under the stocks normal daily volume.
Traders are feeling more bullish on shares of Argos Therapeutics, Inc. if you put credence in the fall in short interest. The company had a fall in short interest of -21.09% as of October 13, 2017 from the last reporting period. Short shares fell from 3,429,642 to 2,706,234 over that timeframe. Days to cover decreased from 1.0 to 0.0 and the percentage of shorted shares is 0.07% as of October 13.
These funds have shifted positions in (ARGS). As of the end of the quarter Hightower Advisors, LLC had acquired a total of 5,500 shares growing its position 20.7%. The value of the investment in (ARGS) went from $11,000 to $11,000 a change of 0.0% quarter to quarter. As of quarter end Cutler Group LP had bought 1,300 shares growing its stake by 216.7%. The value of the investment in Argos Therapeutics, Inc. decreased from $0 to $0 decreasing nan% quarter over quarter.
As of quarter end Meeder Asset Management Inc had bought a total of 10,172 shares growing its holdings by 572.1%. The value of the company’s investment in Argos Therapeutics, Inc. went from $1,000 to $2,000 a change of $1,000 for the reporting period. Sanders Morris Harris Inc. reduced its stake by selling 9,000 shares a decrease of 6.4% from 06/30/2017 to 09/30/2017. Sanders Morris Harris Inc. claims 132,212 shares valued at $23,000. The total value of its holdings decreased 55.8%.
The company is now unchanged from yesterday’s close of $0.15. Shares last traded at $0.15 which is significantly below $0.17, the 50 day moving average and which is significantly lower than the 200 day moving average of $0.30. The 50 day moving average went down $-0.02 or -13.74% whereas the 200 day moving average was down $-0.15 or -50.27%.
As of the latest earnings report the EPS was $-1.49 and is estimated to be $-1.19 for the current year with 54,974,000 shares currently outstanding. Next quarter’s EPS is expected be $-0.20 with next year’s EPS projected to be $-0.48.
Argos Therapeutics, Inc. (Argos), launched on May 8, 1997, is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. Its product candidates include AGS-003 and AGS-004..